Investigational drug · Phase 3
INCA33890
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CRC (Colorectal Cancer).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "INCA33890"
First trial start
2026
Mar 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INCA33890", any sponsor or status.
Conditions studied
As listed on its trial records.
- CRC (Colorectal Cancer)
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INCA33890" as an intervention, largest first.
Incyte CorporationIncyte (INCY)
NCT06179160 · 710 participants (planned) · Start Jan 4, 2024 · Primary completion Jan 1, 2027
Drug: INCB161734; Cetuximab and 6 more · For: Solid Tumors
Sites: Phoenix, Arizona; Palo Alto, California; Santa Monica, California · 34 sites in all
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07284849 · 700 participants (planned) · Start Mar 5, 2026 · Primary completion Dec 29, 2028
Drug: INCA33890; Placebo and 2 more · For: CRC (Colorectal Cancer)
Sites: Mobile, Alabama; Tucson, Arizona; Fountain Valley, California · 297 sites in all
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsRecruiting
Incyte CorporationIncyte (INCY)
NCT05836324 · 570 participants (planned) · Start Jul 24, 2023 · Primary completion May 3, 2029
Drug: INCA33890; bevacizumab and 4 more · For: Solid Tumors; Advanced Solid Tumors; Metastatic Solid Tumors
Sites: Los Angeles, California; Boston, Massachusetts; Grand Rapids, Michigan · 39 sites in all
- A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.Not yet recruiting
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT07876414 · 78 participants (planned) · Start Feb 2027 · Primary completion Feb 2030
Drug: INCA33890; Pembrolizumab · For: Head and Neck Cancer Squamous Cell Carcinoma
Incyte CorporationIncyte (INCY)
NCT07823322 · 40 participants (planned) · Start Dec 14, 2026 · Primary completion May 14, 2029
Drug: INCA33890 · For: CRC (Colorectal Cancer)
Sites: Duarte, California; Glendale, California; Irvine, California · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for CRC (Colorectal Cancer)
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- Decoy20Phase 21 trial
Indaptus Therapeutics, Inc · Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
- NGM120Phase 21 trial
NGM Biopharmaceuticals, Inc · Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.